THOMAS SCIASCIA - 25 Mar 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Scientific Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
25 Mar 2025
Net transactions value
-$13,602
Form type
4
Filing time
26 Mar 2025, 16:30:14 UTC
Previous filing
12 Mar 2025
Next filing
03 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $3,762 +2,631 +1.2% $1.43 224,004 25 Mar 2025 Direct F1
transaction TRVI Common Stock Sale $17,365 -2,631 -1.2% $6.60 221,373 25 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -2,631 -100% $0.000000 0 25 Mar 2025 Common Stock 2,631 $1.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,058 shares purchased through the Issuer's employee stock purchase plan.
F2 This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.